Q1 · MEDICINE
Article
Author: Weeks, Suzanne ; Yeo, Pauline ; Tomaselli, Kevin J. ; Gu, Xin ; Groessl, Todd ; McQuiston, Jeff ; Karanewsky, Donald S. ; Chen, Long-Shiuh ; Aja, Teresa ; Kalish, Vincent J. ; Linton, Steven D. ; Meduna, Steven P. ; Ternansky, Robert J. ; Sebring, Kristen ; Zhang, Cheng-zhi ; Wu, Joe C. ; Chen, Ning ; Hoglen, Niel C. ; Sayers, Robert O. ; Robinson, Edward D. ; Hirakawa, Brad P. ; Herrmann, Julia ; Contreras, Patricia ; Krebs, Joseph ; Armstrong, Robert A. ; Diaz, Jose-Luis ; Bai, Xu ; Valentino, Karen L. ; Spada, Alfred P. ; Ullman, Brett R. ; Winn, David ; Gladstone, Patricia ; Kodandapani, Lalitha ; Ching, Brett ; Fritz, Lawrence C. ; Nalley, Kip ; Fisher, Craig D. ; Jahangiri, Kathy G.
A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of alpha-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.